LLY
USDEli Lilly and Company Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$891.410
Максимум
$915.220
Минимум
$883.640
Объем
6.58M
Фундаментальные показатели компании
Рыночная капитализация
806.5B
Отрасль
Drug Manufacturers - General
Страна
United States
Статистические данные торговли
Средний объем
4.52M
Биржа
NYQ
Валюта
USD
52-недельный диапазон
Отчет об анализе ИИ
Последнее обновление: 3 нояб. 2025 г.Eli Lilly (LLY): Navigating Growth Amid Competitive Obesity Drug Landscape
Market Snapshot
Current Price: $896.53 (as of 2025-11-03) 52-Week Range: $623.78 - $935.63 Volume Surge: 5.4M shares traded today vs. average of 4.5M
Key Trends Driving Recent Performance
- Obesity Drug Dominance:
- LLY announced a €2.6B Dutch plant to boost production of its weight-loss pill orfaglipron, signaling aggressive scaling.
- Partnerships like the Walmart Zepbound retail rollout (mid-Nov 2025) expand market access.
- Analyst Optimism:
- 27 analysts maintain "Buy" ratings; average price target of $919.
Связанные новости
Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter
Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports
Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter.
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight
Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.
Novo Nordisk says Metsera bid won't raise antitrust issues
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.
Lilly to build $3 billion Dutch plant to boost weight-loss pill production
Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines.
Прогноз ИИBeta
Рекомендация ИИ
Обновлено в: 5 нояб. 2025 г., 06:40
54.3% Уверенность
Риск и торговля
Точка входа
$862.58
Взять прибыль
$880.15
Остановить убытки
$837.81
Ключевые факторы
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.